207 related articles for article (PubMed ID: 22476901)
1. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Hoffman KL; Lerner SP; Smith CL
Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
[TBL] [Abstract][Full Text] [Related]
4. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
6. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
7. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
8. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of silver nanoparticles on proliferation of estrogen-dependent MCF-7/BUS human breast cancer cells induced by butyl paraben or di-n-butyl phthalate.
Roszak J; Smok-Pieniążek A; Domeradzka-Gajda K; Grobelny J; Tomaszewska E; Ranoszek-Soliwoda K; Celichowski G; Stępnik M
Toxicol Appl Pharmacol; 2017 Dec; 337():12-21. PubMed ID: 29074358
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
12. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells.
Tu Z; Ma Y; Tian J; Li H; Akers W; Achilefu S; Gu Y
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1091-103. PubMed ID: 22398780
[TBL] [Abstract][Full Text] [Related]
15. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
16. Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine.
Sanaei M; Kavoosi F; Arabloo M
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1045-1050. PubMed ID: 32334468
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective action of raloxifene against hypoxia-induced damage in mouse hippocampal cells depends on ERα but not ERβ or GPR30 signalling.
Rzemieniec J; Litwa E; Wnuk A; Lason W; Gołas A; Krzeptowski W; Kajta M
J Steroid Biochem Mol Biol; 2015 Feb; 146():26-37. PubMed ID: 24846829
[TBL] [Abstract][Full Text] [Related]
18. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
[TBL] [Abstract][Full Text] [Related]
19. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]